1. Home
  2. YSS vs ERAS Comparison

YSS vs ERAS Comparison

Compare YSS & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YSS

York Space Systems Inc. Common Stock

N/A

Current Price

$20.52

Market Cap

3.6B

Sector

Industrials

ML Signal

N/A

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$19.18

Market Cap

4.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YSS
ERAS
Founded
2012
2018
Country
United States
United States
Employees
710
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
4.0B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
YSS
ERAS
Price
$20.52
$19.18
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
12
Target Price
$36.56
$14.25
AVG Volume (30 Days)
1.6M
5.5M
Earning Date
03-19-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
36.23
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$48.43
N/A
Revenue Next Year
$52.83
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.93
$1.33
52 Week High
$44.54
$24.28

Technical Indicators

Market Signals
Indicator
YSS
ERAS
Relative Strength Index (RSI) 35.01 73.23
Support Level $20.31 $12.36
Resistance Level $36.36 $24.28
Average True Range (ATR) 2.59 1.21
MACD -0.57 0.32
Stochastic Oscillator 6.25 90.66

Price Performance

Historical Comparison
YSS
ERAS

About YSS York Space Systems Inc. Common Stock

York Space Systems Inc is a U.S.-based space and defense company that provides mission-related solutions for national security, government, and commercial customers. The company develops its own hardware and software, offering capabilities intended to support customer requirements across various elements of the space mission lifecycle. It offers mission solutions across several complementary product categories: Components, Subsystems, Spacecraft Platforms, Ground Operation, Global Downlink, and Software-Enabled Services. The company derives the majority of revenue from long-term firm-fixed-price (FFP) production contracts for the design of small satellites, launch services, and ground services with both U.S. federal government-controlled agencies and domestic commercial customers.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: